Cannabis-based medicinal products
11/11/2019
Source: NICE (National Institute for Health and Care Excellence)
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
You may also be interested in
11/01/2021
Cannabidiol (CBD) guidance
04/12/2020
UN Commission on Narcotic Drugs reclassifies cannabis to recognize its therapeutic uses
22/01/2021
FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
06/07/2021
Cannabis-based products for medicinal use: Frequently asked questions
01/11/2019
Cannabis (Marijuana) and Cannabinoids: What You Need To Know
01/01/2018
The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018
13/01/2021
Guidance on analytical limits for controlled cannabinoids
17/06/2020
Drug licensing factsheet: cannabis, CBD and other cannabinoids